Clinical Trial Update: PRC-063 Classroom Study in Children (6-12 Years of Age) With ADHD [Phase 3]

View source ↗

Summary

Phase 3 classroom study of PRC-063 in children aged 6-12 with ADHD has completed and results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Attention Deficit Hyperactivity Disorder

Drugs mentioned

• PRC-063 (PRC-063)

Snippet

Sponsor: Purdue Pharma, Canada | Conditions: ADHD | Phase 3 | Status: COMPLETED | Results posted: 2019-06-04